MAZE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Maze Therapeutics Inc (MAZE) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has promising drug candidates and positive analyst sentiment, the technical indicators suggest a bearish trend, and the financials are weak with no revenue and significant losses. The lack of recent trading signals and congress trading data further supports a cautious approach.
The MACD histogram is negative (-2.128) and contracting, indicating a bearish trend. RSI is at 14.259, signaling the stock is oversold. Moving averages are converging, showing no clear trend. Key support level is at 29.444, and the stock is trading near this level at 28.51, suggesting potential downside risk.
The company's pipeline is considered differentiated and competitive, with potential for high revenue generation.
Technical indicators are bearish, and there is no recent congress trading data or strong trading signals to support a buy.
In Q4 2025, the company reported no revenue growth (0% YoY) and a net income loss of -$34.57M, albeit an improvement of 604.61% YoY. EPS improved to -0.65 (up 490.91% YoY), but gross margin dropped to 0, indicating no profitability.
Analyst sentiment is positive, with firms like JPMorgan, Raymond James, and H.C. Wainwright raising price targets significantly and maintaining strong buy or overweight ratings. The target prices range from $46 to $110, reflecting high expectations for the company's drug pipeline.
